4basebio PLC 4BB

Collaboration extends existing relationship with the Tier 1 pharmaceutical customer into cell therapy programsEnd-to-end supply chain combines 4basebio's proprietary opDNA® enzymatic DNA starting material with TriLink's industry-leading GMP mRNA manufacturing capabilities and proprietary CleanCap® co-transcriptional capping technology CAMBRIDGE, UK – 28 September, 2026 – 4basebio PLC (AIM: 4BB), a specialist in enzymatically-produced DNA for new genetic medicines, announces they will supply clin

Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.

Commercial collaboration combines 4basebio’s synthetic DNA technology with Genezen’s viral vector development and manufacturing expertise to support gene therapy programs from early development through clinical and commercial manufacturing. CAMBRIDGE, UK and INDIANAPOLIS, IN – 26 August 2026 – 4basebio PLC (AIM: 4BB), a specialist in enzymatically-produced, cell-free DNA for new genetic medicines, and Genezen, a best-in-class viral vector contract development and manufacturing organization (CDMO

4basebio PLC (AIM:4BB, FRA:8L7, ETR:88Q) CEO Amy Walker joined Proactive's Stephen Gunnion to discuss the company's synthetic DNA platform, growing commercial momentum and key milestones for investors. Walker explained how 4basebio's enzyme-based technology provides a cleaner, faster and more cost-effective alternative to conventional plasmid DNA manufacturing, supporting applications in cell and gene therapy, vaccines and gene editing. She also highlighted the launch of the company's single-stranded DNA product, which offers lower toxicity and the ability to produce longer DNA molecules for a

Dr. Coller, a Bloomberg Distinguished Professor of RNA Biology and Therapeutics, brings deep expertise to accelerate synthetic DNA and mRNA manufacturingDr. Coller’s laboratory team has made seminal discoveries in the area of messenger RNA stability and translation CAMBRIDGE, UK – June 15, 2026 – 4basebio PLC (AIM: 4BB), a specialist in specialist in synthetic DNA manufacturing for next-generation genomic medicines and advanced therapies, today announces the appointment of Jeff Coller, Ph.D., to

CAMBRIDGE, UK – 20 May 2026 – 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces its audited final results for the year ended 31 December 2025. FINANCIAL HIGHLIGHTS Revenue for the period of £1.7 million (FY 2024: £0.9 million), representing growth of 81%, with revenue from clinical stage projects contributing £1.1 million (FY 2024: £0.5 million), and DNA sales revenue increasing by 100%Loss for

Richard Bungay appointed as CFO, bringing a strong track record in fundraising, M&A and partnering for listed and private companies, including two major exits and over $400m raised Cambridge, UK, 14 May 2026 – 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the appointment of Richard Bungay as Chief Financial Officer, with effect from July 2026. Richard takes over the role from David Roth, who stepped down from th

4basebio PLC ("4basebio" or the "Company") 4basebio Launches Enzymatic ssDNA Platform Overcomes critical manufacturing and performance bottlenecks associated with traditional chemical synthesis, providing faster and more reliable ssDNA manufacturing to aid commercial scale up4basebio team to present at ASGCT Annual Meeting 2026 in Boston, MA CAMBRIDGE, UK – 11 May 2026 – 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, annou

Seasoned biotechnology commercial leader will drive global growth strategy Commercial team further bolstered by promotions of James Vang and Jennifer Gelman to VP, Business Development and VP, Marketing, respectively CAMBRIDGE, UK, 3 March 2026 – 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the promotion of Christine Wolosin to Chief Commercial Officer. Christine, who joined 4basebio in September 2025 as Vice P